Physiological regulation of MMPs and tPA/PAI in the arterial wall of rats by noradrenergic tone and angiotensin II

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 36-45

  Dab, Houcine ^a,b   Hachani, Rafik ^a   Dhaouadi, Nedra ^a,b   Hodroj, Wassim ^b   Sakly, Mohsen ^a   Randon, Jacques ^b   Bricca, Giampiero ^b   Kacem, Kamel ^a  

^a UNIVERSITY OF CARTHAGE   (Tunisia)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Adrenergic receptor antagonists; angiotensin II; AT1 receptor antagonist; MMPs; norepinephrine; rat vessels; sympathectomy; VSMCs

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; GELATINASE A; GELATINASE B; GUANETHIDINE; LOSARTAN; MESSENGER RNA; NORADRENALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMORAL ARTERY; FIBRINOLYSIS; IN VITRO STUDY; MALE; NONHUMAN; NORADRENERGIC SYSTEM; RAT; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; DENSITOMETRY; FEMORAL ARTERY; GELATIN; GENE EXPRESSION REGULATION; GUANETHIDINE; LOSARTAN; MALE; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NOREPINEPHRINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, INBRED WKY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84859985755     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311428344     Document Type: Article

References (32)

1. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57: 195-202. (Pubitemid 36897685)
2. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 2005; 26: 1333-1341. (Pubitemid 41435466)
3. Nagase H and Brew K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp 2003; (70): 201-212. (Pubitemid 38497226)
4. Malemud CJ. Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front Biosci 2006; 11: 1702-1715. (Pubitemid 43253388)
5. Galis ZS and Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262. (Pubitemid 34633925)
6. Goodfield NE, Newby DE, Ludlam CA and Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985. (Pubitemid 29270426)
7. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936: 226-236. (Pubitemid 32613910)
8. Messerli FH. TIMPs, MMPs and cardiovascular disease. Eur Heart J 2004; 25: 1475-1476. (Pubitemid 39165622)
9. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31. (Pubitemid 40171256)
10. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
11. Unger T and Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 2004; 5 (Suppl 1): S7-10.
12. Wang TL, Yang YH, Chang H and Hung CR. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol 2004; 37: 785-794. (Pubitemid 39194570)
13. Stacy LB, Yu Q, Horak K and Larson DF. Effect of angiotensin II on primary cardiac fibroblast matrix metalloproteinase activities. Perfusion 2007; 22: 51-55. (Pubitemid 47018362)
14. Dendorfer A, Raasch W, Tempel K and Dominiak P. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 1998; 93: 24-29. (Pubitemid 28498126)
15. Balt JC, Mathy MJ, Nap A, Pfaffendorf M and van Zwieten PA. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol 2001; 38: 141-148. (Pubitemid 32634998)
16. Cox SL, Ben A, Story DF and Ziogas J. Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol 1995; 114: 1057-1063.
17. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D, et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 2005; 167: 1429-1442. (Pubitemid 41541428)
18. Dab H, Hachani R, Hodroj W, Sakly M, Bricca G and Kacem K. Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle. Auton Neurosci 2009; 150: 27-32.
19. Cerutti C, Kurdi M, Bricca G, Hodroj W, Paultre C, Randon J, et al. Transcriptional alterations in the left ventricle of three hypertensive rat models. Physiol Genomics 2006; 27: 295-308. (Pubitemid 46708781)
20. Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon MC, Feugier P, et al. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol 2007; 27: 525-531.
21. Sroka IM, Heiss EH, Havlicek L, Totzke F, Aristei Y, Pechan P, et al. A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells. Mol Pharmacol 2010; 77: 255-261.
22. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Körfer R and Figulla HR. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88: 525-530. (Pubitemid 35221972)
23. Supowit SC, Ethridge RT, Zhao H, Katki KA and Dipette DJ. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol 2005; 289: H1169-H1175. (Pubitemid 41208960)
24. Borovsky V, Herman M, Dunphy G, Caplea A and Ely D. CO2 asphyxia increases plasma norepinephrine in rats via sympathetic nerves. Am J Physiol 1998; 274(1 Pt 2): R19-22.
25. Aihara H, Ogawa H, Kasuya A, Yoshida M, Suzuki-Kusaba M, Hisa H, et al. Intrarenal angiotensin converting enzyme inhibition in spontaneously hypertensive rats. Eur J Pharmacol 1999; 373: 35-40. (Pubitemid 29306708)
26. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC and Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480-3487. (Pubitemid 39602227)
27. Heath JW and Burnstock G. Selectivity of neuronal degeneration produced by chronic guanethidine treatment. J Neurocytol 1977; 4: 397-405. (Pubitemid 8136335)
28. Lee M, Hadi M, Halldén G and Aponte GW. Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity. J Biol Chem 2005; 280: 125-136. (Pubitemid 40164973)
29. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66: 10357-10364. (Pubitemid 44799755)
30. Wu TC, Chen YH, Leu HB, Chen YL, Lin FY, Lin SJ, et al. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic Biol Med 2007; 43: 1508-1522.
31. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-2509. (Pubitemid 29228279)
32. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103: 2181-2187. (Pubitemid 32458328)